Avatrombopag
Cat. No.: IBDI-435720
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.
Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution
Online Inquiry
Product Details
| Target |
Thrombopoietin Receptor |
| Molecular Weight |
649.65 |
| Appearance |
Solid |
| Synonyms |
AKR-501, E5501, YM477 |
| Purity |
99.81% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
